ibudilast has been researched along with Reperfusion Injury in 1 studies
Reperfusion Injury: Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined the effect of 3-isobutyryl-2-isopropylpyrazolo[1,5-a]pyridine (ibudilast), which has been clinically used for bronchial asthma and cerebrovascular disorders, on cell viability induced in a model of reperfusion injury." | 3.71 | Ibudilast attenuates astrocyte apoptosis via cyclic GMP signalling pathway in an in vitro reperfusion model. ( Baba, A; Enomoto, R; Lee, E; Matsuda, T; Mori, K; Takuma, K, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Takuma, K | 1 |
| Lee, E | 1 |
| Enomoto, R | 1 |
| Mori, K | 1 |
| Baba, A | 1 |
| Matsuda, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-Center, Open-Label Biomarker Study to Evaluate MN-166 (Ibudilast) in Subjects With Amyotrophic Literal Sclerosis (ALS)[NCT02714036] | Phase 1/Phase 2 | 35 participants (Actual) | Interventional | 2016-05-06 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 other study available for ibudilast and Reperfusion Injury
| Article | Year |
|---|---|
Ibudilast attenuates astrocyte apoptosis via cyclic GMP signalling pathway in an in vitro reperfusion model.
Topics: Alkaloids; Animals; Animals, Newborn; Apoptosis; Astrocytes; Carbazoles; Cell Survival; Cyclic GMP; | 2001 |